NASDAQ · Biotechnology

XBIO (XBIO) Stock

$2.45 -2.09% NASDAQ: XBIO Healthcare

Valuation

MetricValue
Price$2.45
Market Cap$4.62M
P/E Ratio-2.06
P/B Ratio1.01
P/S Ratio1.92
EPS (TTM)$-1.58
52-Week High$13.93
52-Week Low$1.90
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-37.01%
ROA-21.84%
ROCE-42.86%
Gross Margin100.00%
Operating Margin-75.05%
Net Margin-70.03%
Debt/Equity0.00
Current Ratio8.00

Annual Financials (USD)

Metric20212022202320242025
Revenue$1.0M$2.0M$3.0M$3.0M$3.0M
Operating Profit$-6.0M$-7.0M$-5.0M$-4.0M$-3.0M
Net Profit$-6.0M$-7.0M$-4.0M$-4.0M$-3.0M
EPS$-5.39$-4.49$-2.71$-2.57$-1.58
Op Margin-495.1%-393.6%-177.8%-168.2%-95.2%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$20.0M$15.0M$11.0M$7.0M$8.0M
Total Liabilities$1.0M$1.0M$1.0M$1.0M$1.0M
Cash$18.0M$13.0M$9.0M$6.0M$8.0M
Borrowings$0$0$0$0$0

Latest News

Xenetic Biosciences, Inc. Announces That Its Collaboration Partner Received Approval From the Israeli Ministry of Health to Conduct Exploratory, Investigator Initiated Study of DNase I In Combination With Anti-CD19 CAR T Cells in Large B-Cell Lymphoma ACCESS Newswire · Jun 4, 2026 Xenetic Biosciences Showcases Compelling ASCO 2026 Data Demonstrating DNase I Significantly Enhances CAR-T Cell Persistence, Tumor Control, and Survival ACCESS Newswire · Jun 1, 2026 Xenetic Biosciences Reports First Quarter 2026 Financial Results and Highlights Continued Advancement of DNase Oncology Platform ACCESS Newswire · May 13, 2026 Xenetic Biosciences: Q1 Earnings Snapshot Associated Press · May 12, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-5.0M$-5.0M$-4.0M$-3.0M$-2.0M
Investing Cash Flow$0$-1.0M$0$0$0
Financing Cash Flow$0$0$0$0$0
Net Cash Flow$7.0M$-5.0M$-4.0M$-3.0M$2.0M
Free Cash Flow$-5.0M$-5.0M$-4.0M$-3.0M$-2.0M

Valuation & Return Ratios

MetricValue
PEG Ratio—
EV / EBITDA—
FCF Yield-29.67%
Quick Ratio7.93
Interest Coverage—
Return 1Y-22.46%
Return 3Y-20.33%
Return 5Y-83.62%

Ownership

Insiders Held15.77%
Institutions Held7.38%
Institutions Float Held8.76%
Institutional HolderSharesReport Date
Renaissance Technologies, LLC137,4402026-03-31
Geode Capital Management, LLC21,4412026-03-31
Vanguard Capital Management LLC6,7312026-03-31
JTC Employer Solutions Trustee Ltd.2,7002026-03-31
Tower Research Capital LLC (TRC)8062026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ABPAbpro Corporation $0.52 — -0.02 $1.06M 0.00%
CANFCan-Fite BioPharma Ltd. $3.30 -2.37% -0.74 $1.78M 0.00%
CMND $1.62 +0.52% -0.79 $2.41M 0.00%
ENSCEnsysce Biosciences, Inc. $0.26 -1.95% -0.08 $2.38M 0.00%
KALA $0.76 +3.59% -0.76 $14.62M 0.00%

About XBIO

XBIO is led by CEO James F. Parslow, employs 2 people, headquartered in US, publicly traded since 2016.

XBIO stock trades at $2.45 with a market capitalization of $4.62M. The stock is valued at a price-to-earnings (P/E) ratio of -2.06, price-to-book of 1.01, price-to-sales of 1.92. Over the past 52 weeks the stock has ranged between $1.90 and $13.93, and currently trades 82.4% below its 52-week high.

On profitability, XBIO generates a return on equity (ROE) of -37.01%, return on capital employed of -42.86%, an operating margin of -75.05%, a net profit margin of -70.03%.

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides